Microsoft Corp (NASDAQ:MSFT) backed OpenAI, in partnership with startup Color Health, has unveiled a new initiative to harness artificial intelligence in enhancing cancer screening and treatment plans.

This collaboration integrates OpenAI’s AI models into healthcare applications, marking an advancement in medical technology.

Othman Laraki, co-founder and CEO of Color Health, emphasized that the copilot is intended to support doctors by enhancing their decision-making processes, rather than replacing them.

Also Read: Edward Snowden Warns Against OpenAI’s Latest Announcement: ‘This Is A Calculated Betrayal Of The Rights Of Every Person. You Have Been Warned’

Color Health initiated the development of the copilot last year as part of its broader strategy to integrate more AI tools into healthcare.

The collaboration also extends to Moderna Inc (NASDAQ:MRNA) and involves OpenAI’s efforts to automate tasks in clinical trials and other business operations.

The copilot utilizes OpenAI’s APIs to analyze extensive patient data, including risk factors and family history, alongside established clinical guidelines to generate tailored cancer screening schedules.

This assists primary care physicians, who often lack the time or expertise for detailed risk-adjusted screenings, by providing them with comprehensive, actionable insights.

Moreover, the copilot facilitates the assembly of detailed pre-treatment plans that include necessary imaging and lab tests, helping to expedite the treatment process.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Read Next: OpenAI Appoints Cybersecurity Expert And Retired US Army General With NSA Pedigree To Board, Enhancing AI Safety Measures Post-Lobbying Drive

Image via Shutterstock